HI
KLRS

Harbour Investments’s Kalaris Therapeutics KLRS Stock Holding History

Harbour Investments’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$53 Hold
13
– – ﹤0.01% 4671
2026
Q1 		$75 Buy
+13
New +$115 ﹤0.01% 4540
2021
Q4 		– Sell
-1
Closed – – 3778
2021
Q3 		$0 Buy
+1
New +$463 ﹤0.01% 4049

Other funds holding KLRS

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Harbour Investments's KLRS Position: Q2 2026 in Review

Harbour Investments held its Kalaris Therapeutics (KLRS) position steady in Q2 2026 at 13 shares worth $53. The position accounts for ﹤0.01% of the portfolio, ranked #4671.

Harbour Investments first reported a position in KLRS in Q3 2021 and has held it in 3 quarters since. The position peaked at $75 in Q1 2026. 57 funds tracked by Wall St. Rank hold KLRS as of Q2 2026.

  • Harbour Investments held 13 shares of Kalaris Therapeutics worth $53 as of Q2 2026.
  • Harbour Investments left its Kalaris Therapeutics share count unchanged in Q2 2026.
  • Kalaris Therapeutics made up ﹤0.01% of Harbour Investments's portfolio in Q2 2026, its #4671 holding.
  • Harbour Investments first reported a position in Kalaris Therapeutics in Q3 2021 and has held it in 3 quarters since.
  • Harbour Investments's Kalaris Therapeutics position peaked at $75 in Q1 2026.
  • 57 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q2 2026.

Based on Harbour Investments's 13F filing for Q2 2026, filed 12 Aug 2026.